<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179749</url>
  </required_header>
  <id_info>
    <org_study_id>1R01AA023152</org_study_id>
    <nct_id>NCT02179749</nct_id>
  </id_info>
  <brief_title>Mifepristone Treatment of Alcohol Use Disorder</brief_title>
  <official_title>Glucocorticoid Antagonist Treatment of Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scripps Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 8-week, randomized, double-blind, placebo-controlled, 3 arm, parallel groups,
      dose-ranging study of 1-week of treatment with mifepristone (0, 600, 1200 mg/d) given in
      conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drinking</measure>
    <time_frame>Participants will be followed for up to 8 weeks</time_frame>
    <description>Drinking quantity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Craving</measure>
    <time_frame>Participants will be followed for up to 8 weeks</time_frame>
    <description>Alcohol Craving Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Alcohol Use Disorders</condition>
  <condition>Alcohol Abuse</condition>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Experimental: mifepristone 600 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: mifepristone 1200 mg daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo daily, 1-week</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone 1200 mg daily</intervention_name>
    <description>Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.</description>
    <arm_group_label>Experimental: mifepristone 1200 mg daily</arm_group_label>
    <other_name>Korlym</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standardized behavioral therapy</intervention_name>
    <description>Standardized behavioral therapy 1 time per week for 8 week duration.</description>
    <arm_group_label>Experimental: mifepristone 600 mg daily</arm_group_label>
    <arm_group_label>Experimental: mifepristone 1200 mg daily</arm_group_label>
    <arm_group_label>Placebo daily, 1-week</arm_group_label>
    <other_name>Manually-guided therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone 600 mg daily</intervention_name>
    <description>Mifepristone, 300 mg tablets, Two tablets daily/am plus two placebo tablets daily/am for 1-week duration.</description>
    <arm_group_label>Experimental: mifepristone 600 mg daily</arm_group_label>
    <other_name>Korlym</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, Four tablets daily/am for 1-week duration.</description>
    <arm_group_label>Placebo daily, 1-week</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female volunteers, 18-65 years of age

          -  Meets Diagnostic and Statistical Manual (DSM)-V criteria for current alcohol use
             disorder of moderate or greater severity, defined by DSM-V as â‰¥ 4 symptoms

          -  Abstinent a minimum of 3 days (but not more than 30 days) prior to randomization

          -  In acceptable health in the judgment of the study physician, on the basis of
             interview, medical history, physical exam, ECG, urine test and lab tests

          -  Females with childbearing potential must have a negative serum pregnancy test on the
             screening visit and a negative urine pregnancy test at randomization and agree to use
             non-hormonal effective birth control for the study duration and one month thereafter

        Exclusion Criteria:

          -  A medical condition or chronic use of a medication that contraindicates the
             administration of mifepristone

          -  Significant medical disorders or clinically significant findings on ECG (e.g.,
             prolongation of the corrected QT interval,urine or blood tests that increase potential
             risk or interfere with study participation as determined by the Study Physician. Note:
             serum potassium below the normal range must be replaced to normal prior to
             randomization; individuals with serum potassium outside the range of normal will not
             be randomized

          -  Liver function tests more than 3 times the upper limit of normal or elevated bilirubin

          -  Female subjects with childbearing potential who are pregnant, nursing, or refuse to
             use effective non hormonal birth control for the 1-week of medication administration
             and one month thereafter

          -  Meets Diagnostic and Statistical Manual -V criteria for a major Axis I disorder
             including mood or anxiety disorders or substance use disorders other than alcohol or
             nicotine use disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara J. Mason, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Scripps Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Quello, B.A. B.S</last_name>
    <phone>858-784-7327</phone>
    <email>squello@scripps.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Scripps Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Quello, B.A. B.S.</last_name>
      <phone>858-784-7327</phone>
      <email>squello@scripps.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara J. Mason, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol-Related Disorders</keyword>
  <keyword>Substance-Related Disorders</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>Glucocorticoid Antagonists</keyword>
  <keyword>Alcohol Treatment</keyword>
  <keyword>Alcohol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

